| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
40,010,000 |
| Market
Cap: |
490.92(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.86 - $18.69 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 15.9 |
| Insider 3/6 Months : 16.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Co.'s approved drug DANYELZA® (naxitamab-gqgk) was approved by the U.S. Food and Drug Administration for the treatment, in combination with Granulocyte-Macrophage Colony-Stimulating Factor of pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
371,682 |
558,056 |
762,731 |
| Total Buy Value |
$0 |
$2,488,242 |
$3,530,830 |
$5,499,522 |
| Total People Bought |
0 |
2 |
2 |
3 |
| Total Buy Transactions |
0 |
10 |
14 |
17 |
| Total Shares Sold |
39,644 |
189,644 |
339,644 |
339,644 |
| Total Sell Value |
$515,799 |
$1,516,799 |
$2,312,182 |
$2,312,182 |
| Total People Sold |
3 |
3 |
3 |
3 |
| Total Sell Transactions |
5 |
8 |
10 |
10 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gad Thomas |
See remarks |
• • – |
2021-03-15 |
4 |
AS |
$36.79 |
$257,554 |
D/D |
(7,000) |
0 |
|
-4% |
|
| Gad Thomas |
See remarks |
• • – |
2021-03-15 |
4 |
OE |
$2.00 |
$14,000 |
D/D |
7,000 |
7,000 |
|
- |
|
| Gad Thomas |
See remarks |
• • – |
2021-03-10 |
4 |
A |
$0.00 |
$0 |
I/I |
1,029,927 |
1,625,927 |
|
- |
|
| Wedell-Wedellsborg Johan |
Director |
– • – |
2021-03-10 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,029,927) |
4,478,465 |
|
- |
|
| Gad Thomas |
See remarks |
• • – |
2021-03-01 |
4 |
AS |
$35.50 |
$213,029 |
I/I |
(6,000) |
596,000 |
|
-8% |
|
| Gad Thomas |
See remarks |
• • – |
2021-03-01 |
4 |
AS |
$35.51 |
$319,611 |
D/D |
(9,000) |
0 |
|
-8% |
|
| Gad Thomas |
See remarks |
• • – |
2021-03-01 |
4 |
OE |
$2.00 |
$18,000 |
D/D |
9,000 |
9,000 |
|
- |
|
| Gad Thomas |
See remarks |
• • – |
2021-02-16 |
4 |
AS |
$47.09 |
$188,367 |
I/I |
(4,000) |
602,000 |
|
-26% |
|
| Gad Thomas |
See remarks |
• • – |
2021-02-16 |
4 |
AS |
$47.08 |
$329,556 |
D/D |
(7,000) |
0 |
|
-26% |
|
| Gad Thomas |
See remarks |
• • – |
2021-02-16 |
4 |
OE |
$2.00 |
$14,000 |
D/D |
7,000 |
7,000 |
|
- |
|
| Gad Thomas |
See remarks |
• • – |
2021-02-01 |
4 |
AS |
$41.97 |
$167,888 |
I/I |
(4,000) |
606,000 |
|
-15% |
|
| Gad Thomas |
See remarks |
• • – |
2021-02-01 |
4 |
AS |
$41.99 |
$293,897 |
D/D |
(7,000) |
0 |
|
-15% |
|
| Gad Thomas |
See remarks |
• • – |
2021-02-01 |
4 |
OE |
$2.00 |
$14,000 |
D/D |
7,000 |
7,000 |
|
- |
|
| Gad Thomas |
See remarks |
• • – |
2021-01-19 |
4 |
AS |
$46.56 |
$186,230 |
I/I |
(4,000) |
610,000 |
|
-23% |
|
| Gad Thomas |
See remarks |
• • – |
2021-01-19 |
4 |
AS |
$46.51 |
$325,563 |
D/D |
(7,000) |
0 |
|
-23% |
|
| Gad Thomas |
See remarks |
• • – |
2021-01-19 |
4 |
OE |
$2.00 |
$14,000 |
D/D |
7,000 |
7,000 |
|
- |
|
| Gill David N |
Director |
– • – |
2021-01-19 |
4 |
AS |
$46.52 |
$93,045 |
D/D |
(2,000) |
0 |
|
-23% |
|
| Gill David N |
Director |
– • – |
2021-01-19 |
4 |
OE |
$11.16 |
$22,320 |
D/D |
2,000 |
2,000 |
|
- |
|
| Gad Thomas |
See remarks |
• • – |
2021-01-05 |
4 |
AS |
$49.31 |
$197,248 |
I/I |
(4,000) |
614,000 |
|
-31% |
|
| Gad Thomas |
See remarks |
• • – |
2021-01-05 |
4 |
AS |
$49.36 |
$345,509 |
D/D |
(7,000) |
0 |
|
-31% |
|
| Gad Thomas |
See remarks |
• • – |
2021-01-05 |
4 |
OE |
$2.00 |
$14,000 |
D/D |
7,000 |
7,000 |
|
- |
|
| Gad Thomas |
See Remarks |
• • – |
2020-12-28 |
4 |
AS |
$51.98 |
$363,833 |
D/D |
(7,000) |
0 |
|
-33% |
|
| Gad Thomas |
See Remarks |
• • – |
2020-12-28 |
4 |
OE |
$2.00 |
$14,000 |
D/D |
7,000 |
7,000 |
|
- |
|
| Gad Thomas |
See Remarks |
• • – |
2020-12-16 |
4 |
AS |
$53.01 |
$371,065 |
D/D |
(7,000) |
0 |
|
-45% |
|
| Gad Thomas |
See Remarks |
• • – |
2020-12-16 |
4 |
OE |
$2.00 |
$14,000 |
D/D |
7,000 |
7,000 |
|
- |
|
249 Records found
|
|
Page 6 of 10 |
|
|
0.13 (1.07%) 
